HKSE - Delayed Quote • HKD
China Wah Yan Healthcare Limited (0648.HK)
At close: November 17 at 3:59 PM GMT+8
Breakdown
TTM
12/31/2022
12/31/2021
12/31/2020
Total Revenue
40,749.000
33,765.000
1,699.000
9,617.000
Cost of Revenue
21,478.000
20,028.000
909.000
4,392.000
Gross Profit
19,271.000
13,737.000
790.000
5,225.000
Operating Expense
24,717.000
22,805.000
21,837.000
37,016.000
Operating Income
-5,446.000
-9,068.000
-21,047.000
-31,791.000
Net Non Operating Interest Income Expense
-14,115.000
-15,511.000
-16,268.000
-18,101.000
Pretax Income
-16,854.000
-16,632.000
-24,717.000
-52,470.000
Tax Provision
3,326.000
2,593.000
--
--
Net Income Common Stockholders
-20,653.000
-19,225.000
-26,275.000
-50,846.000
Diluted NI Available to Com Stockholders
-20,653.000
-19,225.000
-26,275.000
-50,846.000
Basic EPS
-0.06
-0.06
-0.08
-0.16
Diluted EPS
-0.06
-0.06
-0.08
-0.16
Basic Average Shares
326,037.000
326,037.000
326,037.000
326,037.000
Diluted Average Shares
326,037.000
326,037.000
326,037.000
326,037.000
Total Expenses
46,195.000
42,833.000
22,746.000
41,408.000
Net Income from Continuing & Discontinued Operation
-20,653.000
-19,225.000
-26,275.000
-50,846.000
Normalized Income
-19,525.750
-17,919.060
-30,149.000
-41,407.000
Interest Income
190.000
38.000
1.000
--
Interest Expense
14,305.000
15,549.000
16,269.000
18,101.000
Net Interest Income
-14,115.000
-15,511.000
-16,268.000
-18,101.000
EBIT
-2,549.000
-1,083.000
-8,448.000
-34,369.000
EBITDA
-2,549.000
957.000
-7,254.000
-32,797.000
Reconciled Cost of Revenue
21,478.000
20,028.000
909.000
4,392.000
Reconciled Depreciation
--
2,040.000
1,194.000
1,572.000
Net Income from Continuing Operation Net Minority Interest
-20,653.000
-19,225.000
-26,275.000
-50,846.000
Total Unusual Items Excluding Goodwill
-1,350.000
-1,564.000
3,874.000
-4,396.000
Total Unusual Items
-1,350.000
-1,564.000
3,874.000
647.000
Normalized EBITDA
-1,199.000
2,521.000
-11,128.000
-33,444.000
Tax Rate for Calcs
0.000
0.000
--
--
Tax Effect of Unusual Items
-222.750
-258.060
--
--
12/31/2020 - 1/4/2000
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade